Recently, Omron Healthcare (hereinafter referred to as "Omron") officially launched a new electronic sphygmomanometer (hereinafter referred to as "ECG sphygmomanometer") that can measure electrocardiogram at the same time, making a breakthrough in achieving dual measurement of ECG and blood pressure. Not only can users monitor their blood pressure at home, but they can also detect the risk of atrial fibrillation in time and warn of arrhythmias by detecting electrocardiograms. This brings a more comprehensive and convenient home chronic disease management solution to the majority of hypertensive patients and patients with atrial fibrillation in China, further reflects Omron's perseverance in the cardiovascular business, and continues to promote the early screening and postoperative management of cardiovascular and cerebrovascular diseases, helping to build a healthy China 2030.
Omron's ECG sphygmomanometer was officially launched, leading the "heart" era of intelligent chronic disease management at home
In recent years, hypertension has been recognized as the main cause of atrial fibrillation, a disease associated with cardiogenic cerebral infarction. The relative risk of increased new-onset atrial fibrillation is approximately twice that of hypertensive disorders, and the prevalence in adults is as high as 30 percent [1]. However, atrial fibrillation is insidious and paroxysmal, with about one-third of patients unaware of atrial fibrillation and some paroxysmal atrial fibrillation missed [2]. Therefore, for patients with hypertension and postoperative atrial fibrillation, the prevention, management and monitoring of blood pressure and ECG are particularly crucial. The ECG sphygmomanometer brought by Omron will further expand the ECG monitoring scenarios outside the hospital, realize the home monitoring and self-test of patients, and provide more means for early diagnosis and early screening of atrial fibrillation.
ECG and blood pressure are two-in-one, and dual management is done without leaving home
Omron ECG sphygmomanometer has the function of "blood pressure + ECG" simultaneous monitoring, which brings ECG monitoring methods that can only be carried out in hospitals to the family, which helps patients with hypertension to find the risk of arrhythmia mainly based on atrial fibrillation conveniently and timely, and improves the awareness of patient complication management. In addition, the ECG sphygmomanometer has the function of real-time export of ECG, which can be used as an auxiliary means and an important reference for doctors to diagnose potential patients with atrial fibrillation, which reduces the risk of missed diagnosis due to paroxysmal atrial fibrillation to a certain extent, and brings more possibilities for the screening and prevention of cardiovascular and cerebrovascular diseases in patients.
Omron ECG sphygmomanometer realizes ECG and blood pressure measurement at home at the same time
Early screening of atrial fibrillation risk makes postoperative management more secure
Atrial fibrillation is a cardiovascular disease with a high recurrence rate, and according to the 2023 Chinese Guidelines for the Diagnosis and Treatment of Atrial Fibrillation, asymptomatic atrial fibrillation can be detected at regular follow-up after atrial fibrillation, and intensive monitoring is required [3]. By recording the user's ECG data, the Omron ECG sphygmomanometer can display and analyze the ECG on the mobile phone by linking it with the intelligent APP. The APP will give the analysis results of 4 conditions according to the user's ECG data, including sinus rhythm, suspected atrial fibrillation, tachycardia and bradycardia, to help users identify the risk of arrhythmia in time and achieve early prevention, early screening and early control of atrial fibrillation. On the other hand, the product also helps to reduce the concern of patients diagnosed with atrial fibrillation and postoperative management about recurrence, further improve patients' awareness of "active health", and bring more peace of mind to patients.
Intelligent screening of atrial fibrillation risk helps patients achieve early screening, early treatment and postoperative management of chronic diseases
Directly connected to the APP intelligent analysis, professional, accurate and personalized
As the people's attention to medical and health issues continues to rise, topics such as medical digitalization and smart medical care are increasingly entering the public eye. Implementing the idea of digital and intelligent research and development, Omron ECG sphygmomanometer can be directly connected to the OMRON Plus APP, and uses AI algorithms to intelligently analyze ECG, helping patients achieve personalized and intelligent health management. The software is also continuously upgraded to help users achieve more comprehensive chronic disease health management with a composite management model. Among them, OMRON Plus ECG (ECG Analysis Prompt Software) has been certified as a Class II medical device, and its professional and accurate functions will bring a more intelligent and effective health management experience to the majority of users.
The OMRON Plus app provides personalized health management modes such as ECG management and compound management
Mr. Zhao Yao, Director & General Manager of Omron Healthcare (China) Co., Ltd., said, "For a long time, Omron has adhered to the vision of 'Going for ZERO preventive medicine, making the world healthier', and insisted on driving the development of the industry with innovative products and service models. This year, with the launch of wireless ECG recorders and ECG sphygmomanometers, Omron has taken a solid step in the management of complications of hypertension. In the future, Omron will continue to devote itself to the exploration and innovation in the field of chronic disease management, continuously improve the product matrix, launch innovative solutions to meet the growing needs of patients with chronic diseases, and continue to support the 'Healthy China 2030' strategy, so as to contribute to the realization of national health with the expertise and advantages of the medical and health industry." ”
[1] Lu Juexiu, Liu Xianxia, Yan Lin. Research progress on the prevention of atrial fibrillation in hypertensive patients with RAAS blockers[J].Advances in Clinical Medicine,2023,13(2):1925-1932.)
[2] Du X, Guo L, Xia S, et al. Atrial fibrillation prevalence, awareness and management in a nationwide survey of adults in China[J]. Heart, 2021, 107(7): 535‑541. DOI: 10.1136/heartjnl‑2020‑317915
[3] Chinese Society of Cardiovascular Diseases, Chinese Society of Biomedical Engineering. Chinese guidelines for the diagnosis and treatment of atrial fibrillation[J].Chinese Journal of Cardiovascular Diseases,2023,51(6):572-618.DOI:10.3760/cma.j.cn112148-20230416-00221.
(Xianning News Network)